Victory Capital Management Inc Exagen Inc. Transaction History

Victory Capital Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 02, 2021	SELL	$10.25 - $15.21 $372,536 - $552,807	-36,345 Closed	0 $0
Q2 2021 Aug 03, 2021	SELL	$12.4 - $17.92 $439,294 - $634,851	-35,427 Reduced 49.36%	36,345 $545,000
Q1 2021 May 04, 2021	SELL	$13.9 - $22.0 $18,487 - $29,260	-1,330 Reduced 1.82%	71,772 $1.26 Million
Q4 2020 Feb 01, 2021	SELL	$11.19 - $16.05 $50,019 - $71,743	-4,470 Reduced 5.76%	73,102 $965,000
Q3 2020 Nov 09, 2020	SELL	$10.56 - $16.69 $36,326 - $57,413	-3,440 Reduced 4.25%	77,572 $841,000

Q2 2020 Aug 07, 2020	SELL	$11.0 - $16.7 $3.28 Million - $4.98 Million	-298,172 Reduced 78.64%	81,012 $1.01 Million
Q1 2020 May 04, 2020	SELL	$12.7 - $25.95 $112,903 - $230,695	-8,890 Reduced 2.29%	379,184 $6.04 Million
Q4 2019 Feb 06, 2020	SELL	$12.61 - $28.48 $13,467 - $30,416	-1,068 Reduced 0.27%	388,074 $9.86 Million
Q4 2019 Feb 04, 2020	SELL	$12.61 - $28.48 $452,169 - $1.02 Million	-35,858 Reduced 8.44%	389,142 $8.04 Million
Q3 2019 Nov 12, 2019	BUY	$14.5 - $17.5 $6.16 Million - $7.44 Million	425,000 New	425,000 $6.58 Million

6.21M

1.6K

4.1K

Ticker XGN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 16,260,400
Market Cap $28.9M
Description
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus ery...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.